Acsel Health, an OPEN Health Company
Supporting you through your HTA journey, from initial strategy to reimbursement and launch
The power of early strategic advice to ensure high-quality trial designs.
OPEN Health can provide comprehensive, early strategic advice to ensure your trial meets HTA bodies’ requirements, maximizing chances of success.
Strategic advice can encompass:
Our specialist teams in market access strategy and health economic modeling and meta-analysis work seamlessly together to support you, with a designated project manager to ensure clear communication and collaboration across the entire HTA process.
Supplement clinical trial data during submissions to demonstrate differential value post launch.
OPEN Health offers a complete real-world evidence (RWE) solution, starting with a strong consultancy platform to support our clients to define potential data gaps and the most optimal solutions for RWE generation.
Click on each section to read more.
Lysosomal storage disorders (LSDs) are a group of rare diseases with a wide range of symptoms. Diagnosis is often delayed due to variations in patient characteristics and access to specialist centers and testing.
The client needed an approach that yielded multiple outcomes. These included HTA submission, pathway analysis and burden quantification, and the development of an algorithm to identify patients with potentially undiagnosed LSDs.
Using the Clinical Practice Research Datalink and Optimum Patient Care Research Database plus Hospital Episode Statistics, an analysis was undertaken to determine the disease and natural history characteristics of LSD patients. Economic burden and disease pathways were described and quantified and validated with KOLs.
Using a variety of machine learning technologies, a patient-finding algorithm was developed. It was tested and validated with KOLs and provided to the NHS. In addition, a disease burden payer engagement model was developed, and a pathway and outcome analysis provided to NICE.
Regulatory and HTA submissions require the integration of the patient voice to contextualize the results observed in clinical trials.
Through decades of helping bring innovative therapies to market, we understand the patient’s perspective and how to develop patient-centric studies.
Learn more about including patients’ perspectives with these resources.
This whitepaper presents a cross-discipline review of how we can improve patient involvement and understanding across the HEOR process.
In this webinar, we address all facets of burden with patient advocates and experts in rare disease, health technology assessments and patient-centred outcomes.
As digital health becomes an increasingly common feature on the healthcare landscape, digital therapeutics have gained a lot of attention from both regulatory and HTA authorities.
Our market access expertise can guide you to the right digital tool to enhance your project.View our white papers to learn more about the adoption of digital health technologies.
To learn more about our HTA capabilities and discuss what we could do for you, please get in touch.